Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019
NEW YORK, Feb. 29, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019
http://www.reportlinker.com/p0358214/Melanoma-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, "Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global melanoma therapeutics market. The report identifies the key trends shaping and driving the global melanoma therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global melanoma therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimates that the global melanoma therapeutics market was worth $0.8 billion in 2011, after increasing at a Compound Annual Growth Rate (CAGR) of 22.8% during 2006–2011. During 2011–2019, the market is expected to record a CAGR of 16.6%, from $0.8 billion in 2011 to $2.6 billion in 2019. The current treatment options for melanoma include -
- Newly approved targeted therapies such as Yervoy(ipilimumab) and Zelboraf(vemurafenib)
- Adjuvant therapies such as Intron-A (interferon alfa-2b) and Sylatron(peg-interferon alfa-2b)
- Immunotherapy such as Proleukin(aldesleukin)
- Cytotoxics such as dacarbazine and other off-label drugs including temozolomide, cisplatin and paclitaxel.
The growth of the market is primarily due to the new product approvals and increase in the incidence rates during the forecast period. Due to these factors, the melanoma therapeutics market is expected to show robust growth until 2019.
Scope
The report provides information on the key drivers and challenges of the melanoma therapeutics market. Its scope includes -
- Annualized revenues data for seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) in the melanoma therapeutics market from 2006-2011 and forecasts for 2011-2019.
- Pipeline analysis data split across the different phases of development, mechanisms of action being developed and emerging trends. Pipeline candidates fall under the major therapeutic classes of immunotherapies, tyrosine kinase inhibitors, microtubule inhibitors, MEK inhibitors, BRAF inhibitors and anti-VEGF monoclonal antibody.
- Analysis of the current and future competition in the global melanoma therapeutics market. The key market players covered are AB Science, Amgen, Bristol-Myers Squibb, Celgene, Eisai, F-Hoffmann-La Roche, GlaxoSmithKline, Plexxikon and vical Incorporated.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet need and implications for the melanoma therapeutics market.
- Analysis of key recent licensing and partnership agreements in the melanoma therapeutics market
Reasons to buy
The report will enhance your decision-making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global melanoma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global melanoma therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global melanoma therapeutics market landscape? Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 7
2 Melanoma Therapeutics - Introduction 8
2.1 Appearance and Location 8
2.2 Symptoms 8
2.2.1 ABCDE System 8
2.2.2 Other Signs of Melanoma 9
2.3 Etiology 9
2.3.1 Environmental Factor 9
2.3.2 Genetic Mutation 9
2.4 Pathophysiology 10
2.5 Risk Factors 10
2.6 Types of Melanoma 11
2.7 Epidemiology 12
2.8 Screening Guidelines for Melanoma 13
2.9 Diagnosis and Treatment Guidelines for Melanoma 14
2.10 Diagnosis 14
2.10.1 Early Detection of Melanoma 14
2.10.2 Types of Skin Biopsy 14
2.10.3 Pathology Report 15
2.10.4 Diagnostic Indicators 16
2.10.5 Procedures and Tests to Detect Metastases 16
2.10.6 Other Secondary Tests 17
2.10.7 Diagnostic Algorithm 18
2.10.8 Approval of New Diagnostic Devices 18
2.11 Staging 19
2.11.1 Stage 0 22
2.11.2 Stage IA 22
2.11.3 Stage IIA 22
2.11.4 Stage IIB 22
2.11.5 Stage IIC 22
2.11.6 Stage IIIA 22
2.11.7 Stage IIIB 22
2.11.8 Stage IIIC 22
2.11.9 Stage IV 22
2.11.10 Broad Staging of Melanoma 23
2.11.11 Survival Rates by Stage 23
2.12 Treatment 24
2.12.1 Surgery 24
2.12.2 Non-surgical 25
2.12.3 Treatment by Stage 28
2.13 GlobalData Pipeline Report Guidance 36
3 Melanoma Therapeutics - Market Characterization 37
3.1 Melanoma Therapeutics Market Size (2006-2011) - Global 37
3.2 Melanoma Therapeutics Market Forecast (2011-2019) - Global 39
3.3 Melanoma Therapeutics Market Size (2006-2011) - The US 41
3.4 Melanoma Therapeutics Market Forecast (2011-2019) - The US 42
3.5 Melanoma Therapeutics Market Size (2006-2011) - The UK 43
3.6 Melanoma Therapeutics Market Forecast (2011-2019) - The UK 44
3.7 Melanoma Therapeutics Market Size (2006-2011) - France 45
3.8 Melanoma Therapeutics Market Forecast (2011-2019) - France 46
3.9 Melanoma Therapeutics Market Size (2006-2011) - Germany 47
3.10 Melanoma Therapeutics Market Forecast (2011-2019) - Germany 48
3.11 Melanoma Therapeutics Market Size (2006-2011) - Italy 49
3.12 Melanoma Therapeutics Market Forecast (2011-2019) - Italy 50
3.13 Melanoma Therapeutics Market Size (2006-2011) - Spain 51
3.14 Melanoma Therapeutics Market Forecast (2011-2019) - Spain 52
3.15 Melanoma Therapeutics Market Size (2006-2011) - Japan 53
3.16 Melanoma Therapeutics Market Forecast (2011-2019) - Japan 54
3.17 Drivers and Barriers for the Melanoma Therapeutics Market 55
3.17.1 Drivers for the Melanoma Therapeutics Market 55
3.17.2 Barriers for the Melanoma Therapeutics Market 55
3.18 Opportunity and Unmet Need 56
3.18.1 Opportunity and Unmet Need for the Metastatic Melanoma Therapeutics Market 56
3.19 Key Takeaway 58
4 Melanoma Therapeutics Market - Competitive Assessment 59
4.1 Overview 59
4.2 Strategic Competitor Assessment 59
4.2.1 Competitor Assessment within Different Categories Employed in Melanoma Therapeutics Treatment 60
4.3 Product Profiles for Recommended Drugs in Melanoma Therapeutics Market 62
4.3.1 Yervoy (ipilimumab) 62
4.3.2 Zelboraf (vemurafenib) 64
4.3.3 Sylatron (peg-interferon alfa-2b) 67
4.3.4 DTIC-Dome (dacarbazine) 69
4.3.5 Intron A (high-dose interferon alfa-2b) 70
4.3.6 Proleukin (aldesleukin or Interleukin-2 or IL-2) 71
4.3.7 Temodar (temozolomide, Temodal in the UK and Europe) 73
4.4 Key Takeaway 73
5 Melanoma Therapeutics - Pipeline Assessment 74
5.1 Overview 74
5.2 Strategic Pipeline Assessment 74
5.3 Melanoma Therapeutics - Pipeline by Phases of Development 75
5.3.1 Melanoma Therapeutics - Phase III Pipeline 76
5.3.2 Melanoma Therapeutics - Phase II Pipeline 77
5.3.3 Melanoma Therapeutics - Phase I/II Pipeline 80
5.3.4 Melanoma Therapeutics - Phase I Pipeline 82
5.3.5 Melanoma Therapeutics - Preclinical Pipeline 86
5.3.6 Melanoma Therapeutics - Discovery Pipeline 87
5.4 Melanoma Therapeutics- Pipeline by Mechanism of Action 88
5.5 Pipeline by Line of Therapy 91
5.5.1 Technology Trends Analytic Framework 92
5.6 Molecule Profiles of Key Late Stage Drugs under Clinical Development 94
5.6.1 Abraxane (ABI-007) 94
5.6.2 Allovectin-7 95
5.6.3 Avastin (bevacizumab) 96
5.6.4 Dabrafenib (GSK2118436) 96
5.6.5 MAGE-A3 97
5.6.6 Masitinib (AB1010) 98
5.6.7 OncoVEXGM-CSF (talimogene laherparepvec) 98
5.6.8 Tasigna (nilotinib) 99
5.6.9 Trametinib (GSK1120212) 99
5.7 Key Takeaway 100
6 Melanoma Therapeutics - Clinical Trials Mapping 101
6.1 Clinical Trials by Country (US, EU5 and Japan) 101
6.2 Clinical Trials by Phase 102
6.3 Clinical Trials by Status 103
6.4 Overall Sponsors 104
6.5 Prominent Sponsors 105
6.6 Top Companies Participating in Melanoma Therapeutics Clinical Trials 107
7 Melanoma Therapeutics - Strategic Assessment 109
7.1 Melanoma Therapeutics - Implications for Future Market Competition 109
8 Mlenaoma Therapeutics - Future Players 110
8.1 Introduction 110
8.2 Company Profiles 111
8.2.1 AB Science 111
8.2.2 Amgen Inc. 112
8.2.3 Bristol-Myers Squibb 113
8.2.4 Celgene Corporation 115
8.2.5 Eisai Co., Ltd. 117
8.2.6 F. Hoffmann-La Roche Ltd. 119
8.2.7 GlaxoSmithKline plc 122
8.2.8 Novartis AG 124
8.2.9 Vical Incorporated 126
9 Licenising and Partnership Deals 128
10 Melanoma Therapeutics - Appendix 131
10.1 Definitions 131
10.2 Acronyms 131
10.3 Research Methodology 132
10.3.1 Coverage 132
10.3.2 Secondary Research 133
10.3.3 Forecasting 133
10.3.4 Primary Research 135
10.3.5 Expert Panel Validation 136
10.4 Contact Us 136
10.5 Disclaimer 136
10.6 Bibliography 136
1.1 List of Tables
Table 1: Melanoma, Diagnosis and Treatment Guidelines 11
Table 2: Melanoma Incidence, 2008-2020 13
Table 3: Screening Guidelines for Early Detection of Melanoma 13
Table 4: Melanoma, Diagnosis and Treatment Guidelines 14
Table 5: Melanoma, Principles of Pathology 15
Table 6: Clark Levels 16
Table 7: Melanoma TNM System Description 19
Table 8: Melanoma Anatomic Stage/Prognostic Groups 21
Table 9: Melanoma, Survival Rate 23
Table 10: Principles of Surgical Margins for Wide Excision of Primary Melanoma 25
Table 11: Major Systemic Therapies for Melanoma 26
Table 12: Cytotoxic Drugs Used for the Treatment of Advanced Melanoma 35
Table 13: Melanoma Therapeutics Market, Global, Revenue ($bn), 2006-2011 37
Table 14: Melanoma Therapeutics Market, Global, Forecast ($bn), 2011-2019 39
Table 15: Melanoma Therapeutics Market, The US, Revenue ($bn), 2006-2011 41
Table 16: Melanoma Therapeutics Market, The US, Forecast ($bn), 2011-2019 42
Table 17: Melanoma Therapeutics Market, The UK, Revenue ($m), 2006-2011 43
Table 18: Melanoma Therapeutics Market, The UK, Forecast ($m), 2011-2019 44
Table 19: Melanoma Therapeutics Market, France, Revenue ($m), 2006-2011 45
Table 20: Melanoma Therapeutics Market, France, Forecast ($m), 2011-2019 46
Table 21: Melanoma Therapeutics Market, Germany, Revenue ($m), 2006-2011 47
Table 22: Melanoma Therapeutics Market, Germany, Forecast ($m), 2011-2019 48
Table 23: Melanoma Therapeutics Market, Italy, Revenue ($m), 2006-2011 49
Table 24: Melanoma Therapeutics Market, Italy, Forecast ($m), 2011-2019 50
Table 25: Melanoma Therapeutics Market, Spain, Revenue ($m), 2006-2011 51
Table 26: Melanoma Therapeutics Market, Spain, Forecast ($m), 2011-2019 52
Table 27: Melanoma Therapeutics Market, Japan, Revenue ($m), 2006-2011 53
Table 28: Melanoma Therapeutics Market, Japan, Forecast ($m), 2011-2019 54
Table 29: Survival Rates of Yervoy Versus gp100 Arm 62
Table 30: Severe to Fatal Immune-Mediated Adverse Reactions of Yervoy 63
Table 31: Severe Adverse Events of Yervoy 63
Table 32: Efficacy Results of Zelboraf Versus Decarbazine in the BRIM3 Dtudy 65
Table 33: Adverse Reactions Reported in ? 10% of Patients Treated with Zelboraf in the BRIM3 Study 66
Table 34: Adverse Reactions Reported in ? 10% of Patients Treated with Zelboraf in the BRIM2 Study 67
Table 35: Adverse Reactions Occurring in ? 5% of Melanoma Patients 68
Table 36: Sylatron Dose Modification 69
Table 37: Intron A Dosage Forms for Malignant Melanoma 71
Table 38: Efficacy Results of Melanoma 72
Table 39: Responses of Proleukin 72
Table 40: Melanoma - Phase III Pipeline 76
Table 41: Melanoma - Phase II Pipeline 77
Table 42: Melanoma - Phase I/II Pipeline 80
Table 43: Melanoma - Phase I Pipeline 82
Table 44: Melanoma - Preclinical Pipeline 86
Table 45: Melanoma - Discovery Pipeline 87
Table 46: Melanoma Therapeutics - Mechanism of Action that Constitute 'Others' 89
Table 47: Melanoma Therapeutics, Global, Pipeline by Line of Therapy, 2011 91
Table 48: Melanoma Therapeutics Market, Global, Clinical Trials by Country, November 2011 101
Table 49: Melanoma Therapeutics Market, Global, Clinical Trials by Phase, November 2011 102
Table 50: Melanoma Therapeutics Market, Global, Clinical Trials by Status, November 2011 103
Table 51: Melanoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, November 2011 104
Table 52: Melanoma Therapeutics Market, Global, Clinical Trials, Leading Sponsors, November 2011 106
Table 53: Melanoma Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, November 2011 108
Table 54: AB Science- Melanoma Pipeline Product, 2012 111
Table 55: Amgen - Promising Molecules in Pipeline for Melanoma, 2011 113
Table 56: Bristol-Myers Squibb - Promising Molecules in Pipeline for Melanoma, 2011 114
Table 57: Celgene Corporation - Melanoma Pipeline Product, 2011 117
Table 58: Eisai Co., Ltd. - Promising Molecules in Pipeline for Melanoma, 2011 119
Table 59: F. Hoffmann-La Roche Ltd. - Promising Molecules in Pipeline for Melanoma, 2011 121
Table 60: GlaxoSmithKline plc- Promising Molecules in Pipeline for Melanoma, 2011 123
Table 61: Novartis AG - Promising Molecules in Pipeline for Melanoma, 2011 125
Table 62: Vical Incorporated - Melanoma Pipeline Product, 2012 127
Table 63: Melanoma , Global Deals , 2009-2011 128
List of Figures
Figure 1: Melanoma, Treatment Options 24
Figure 2: Melanoma Therapeutics Market, Global, Revenue ($bn), 2006-2011 37
Figure 3: Melanoma Therapeutics, Market Share ($m), 2011 38
Figure 4: Melanoma Therapeutics Market, Global, Forecast ($bn), 2011-2019 39
Figure 5: Melanoma Therapeutics Market, Global, Market Share ($m), 2019 40
Figure 6: Melanoma Therapeutics Market, The US, Revenue ($bn), 2006-2011 41
Figure 7: Melanoma Therapeutics Market, The US, Forecast ($bn), 2011-2019 42
Figure 8: Melanoma Market, The UK, Revenue ($m), 2006-2011 43
Figure 9: Melanoma Therapeutics Market, The UK, Forecast ($m), 2011-2019 44
Figure 10: Melanoma Therapeutics Market, France, Revenue ($m), 2006-2011 45
Figure 11: Melanoma Therapeutics Market, France, Forecast ($m), 2011-2019 46
Figure 12: Melanoma Therapeutics Market, Germany, Revenue ($m), 2006-2011 47
Figure 13: Melanoma Therapeutics Market, Germany, Forecast ($m), 2011-2019 48
Figure 14: Melanoma Therapeutics Market, Italy, Revenue ($m), 2006-2011 49
Figure 15: Melanoma Therapeutics Market, Italy, Forecast ($m), 2011-2019 50
Figure 16: Melanoma Therapeutics Market, Spain, Revenue ($m), 2006-2011 51
Figure 17: Melanoma Therapeutics Market, Spain, Forecast ($m), 2011-2019 52
Figure 18: Melanoma Therapeutics Market, Japan, Revenue ($m), 2006-2011 53
Figure 19: Melanoma Therapeutics Market, Japan, Forecast ($m), 2011-2019 54
Figure 20: Melanoma Therapeutics Market, Drivers and Barriers, 2011 56
Figure 21: Opportunity and Unmet Need for Metastatic Melanoma Therapeutics Market, 2011 57
Figure 22: Opportunity and Unmet Need for BRAF Mutation Positive Metastatic Melanoma Therapeutics Market, 2011 57
Figure 23: Melanoma Therapeutics Market - Strategic Competitor Assessment for Metastatic Melanoma, 2011 60
Figure 24: Melanoma Therapeutics Market - Strategic Competitor Assessment in Adjuvant Setting, 2011 61
Figure 25: Melanoma Therapeutics Pipeline by Phase of Clinical Development, 2011 75
Figure 26: Melanoma Therapeutics, Global, Pipeline by Mechanism of Action, 2011 88
Figure 27: Melanoma Therapeutics, Global, Pipeline by Line of Therapy, 2011 91
Figure 28: Melanoma Therapeutics, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2011 92
Figure 29: Melanoma Therapeutics, Global, Technology Trends Description of Pipeline Drugs, 2011 93
Figure 30: Melanoma Therapeutics Market, Global, Clinical Trials by Country, November 2011 101
Figure 31: Melanoma Therapeutics Market, Global, Clinical Trials by Phase, November 2011 102
Figure 32: Melanoma Therapeutics Market, Global, Clinical Trials by Status, November 2011 103
Figure 33: Melanoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, November 2011 104
Figure 34: Melanoma Therapeutics Market, Global, Clinical Trials, Leading Sponsors, November 2011 105
Figure 35: Melanoma Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, November 2011 107
Figure 36: Implications for Future Market Competition in Melanoma Therapeutics Market, 2011 109
Figure 37: Melanoma Therapeutics - Pipeline by Company, 2011 110
Figure 38: Epidemiology Based Forecasting 133
Figure 39: Market Forecasting Model 135
Companies mentioned
AB Science
Amgen Inc.
Bristol-Myers Squibb
Celgene Corporation
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Novartis AG
Vical Incorporated
To order this report:
Therapy Industry: Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Check our Industry Analysis and Insights
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article